NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 79.9% and is now trading at $21.64.
View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cytokinetics.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Cytokinetics.

Cytokinetics, Inc. (NASDAQ:CYTK) announced its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.16. The biopharmaceutical company earned $3.83 million during the quarter, compared to analysts' expectations of $4.92 million.
View Cytokinetics' earnings history.

Cytokinetics issued an update on its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $18-22 million, compared to the consensus revenue estimate of $24.38 million.

9 equities research analysts have issued 1-year price targets for Cytokinetics' stock. Their forecasts range from $20.00 to $59.00. On average, they anticipate Cytokinetics' share price to reach $37.22 in the next year. This suggests a possible upside of 72.0% from the stock's current price.
View analysts' price targets for Cytokinetics.

Media stories about CYTK stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytokinetics earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Cytokinetics.

Cytokinetics saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 7,720,000 shares, a decrease of 6.3% from the June 15th total of 8,240,000 shares. Based on an average daily trading volume, of 867,200 shares, the short-interest ratio is presently 8.9 days. Approximately 14.2% of the company's stock are short sold.
View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Schrodinger (SDGR), Zai Lab (ZLAB), Myokardia (MYOK), Legend Biotech (LEGN), HUTCHISON CHINA/S (HCM), HYPERA S A/S (HYPMY), GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT) and Amicus Therapeutics (FOLD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Geron (GERN), TherapeuticsMD (TXMD), Gilead Sciences (GILD) and Immunomedics (IMMU).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (1.04%), Principal Financial Group Inc. (0.78%), Asymmetry Capital Management L.P. (0.35%), New York State Teachers Retirement System (0.20%), Swiss National Bank (0.19%) and Mirador Capital Partners LP (0.16%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Russell Investments Group Ltd., UBS Group AG, Virtus ETF Advisers LLC, Envestnet Asset Management Inc., Dupont Capital Management Corp, First Citizens Bank & Trust Co., and Texas Permanent School Fund. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, and Wendall Wierenga.
View insider buying and selling activity for Cytokinetics.

CYTK stock was acquired by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, Swiss National Bank, Sigma Planning Corp, Principal Financial Group Inc., ProShare Advisors LLC, Comerica Bank, Jennison Associates LLC, and Granite Investment Advisors LLC. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $21.64.

Cytokinetics has a market capitalization of $1.29 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

The official website for Cytokinetics is www.cytokinetics.com.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]